Truenat HPV-HR Plus test is critical for closing the screening gap, particularly for asymptomatic women and women who are at higher risk for persistent HPV infection. By shifting HPV screening closer to the most-at-risk people and communities, this test ensures early detection, better triaging, and timely treatment - especially in historically underserved populations.
Over 10,000 Truenat RT-PCR molecular test machines are already deployed globally in over 85 countries (mostly for TB), and mostly in the Global South nations in remote settings. Truenat is a battery operated (with solar power charging), laboratory independent, de-centralised and point-of-care test that provides highly accurate diagnosis for over 30 diseases (including TB, HPV, HCV, HBV, STIs, COVID-19, etc) within an hour - thus enabling same day test and treat, counselling and follow-up.
Superiority of Truenat HPV-HR Plus test
Older Pap smear test detects precancerous or cancerous cervical cancer cells whereas Truenat HPV-HR Plus test detects the presence of high-risk HPV DNA (8 genotypes).
Pap smear is a cytological screening test and depends on the observing medical expert's skill and slide quality, whereas Truenat is a PCR-based nuclear acid amplification test with very high sensitivity and specificity.
False negative reports are higher and false positive reports are also moderate when pap smear is used whereas both are low with Truenat HPV-HR Plus. The most recent validation of Truenat HPV-HR Plus showed 100% specificity and 100% sensitivity.
Truenat HPV-HR is designed to work with cervical swab samples collected by a clinician (self-collection of samples is still under evaluation), and it gives highly accurate results in just 60 minutes. Whereas, a pap smear results may take 3-7 days as these are laboratory dependent.
Easy to use and with high stability at room temperature, Truenat HPV-HR Plus requires minimal biosafety and is optimised for use at both the laboratory and near-patient settings. This test overcomes shortcomings of current diagnostic methods, including variable sensitivity and specificity, high costs, complex workflows, and dependence on advanced equipment, said Dr Sachdeva.
Next Page 1 | 2 | 3 | 4 | 5 | 6 | 7
(Note: You can view every article as one long page if you sign up as an Advocate Member, or higher).
